(2S,3R,4R,5S)-2-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol | 1018898-94-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4R,5S)-2-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol
• 英文别名: (2S,3R,4R,5S)-2-[4-chloro-3-[(4-hydroxyphenyl)methyl]phenyl]-6-methoxyoxane-3,4,5-triol
• CAS: 1018898-94-6
• 化学式: C₁₉H₂₁ClO₆
• 分子量: 380.825
• InChiKey: YSQLKZLRLCWBQK-OKLPXFMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S,3R,4R,5S)-2-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol 、 (S)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以55%的产率得到(2S,3R,4R,5S)-2-[4-chloro-3-[[4-[(3R)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-methoxyoxane-3,4,5-triol
  参考文献：
  名称：

  WO2008/42688

  摘要：

  公开号：

文献信息

• Novel <scp>l</scp>-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes
  作者：Nicole C. Goodwin、Ross Mabon、Bryce A. Harrison、Melanie K. Shadoan、Zheng Y. Almstead、Yiling Xie、Jason Healy、Lindsey M. Buhring、Christopher M. DaCosta、Jennifer Bardenhagen、Faika Mseeh、Qingyun Liu、Amr Nouraldeen、Alan G. E. Wilson、S. David Kimball、David R. Powell、David B. Rawlins

  DOI：10.1021/jm900951n

  日期：2009.10.22

  The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose

  全世界的糖尿病患病率持续上升，已经成为一个主要的健康问题。最近，有几篇针对钠依赖性葡萄糖共转运蛋白2（SGLT2）的抑制剂的报道，作为维持糖尿病患者葡萄糖体内稳态的一种方法。在本文中，我们报道了在体外抑制SGLT2和在体内尿葡萄糖重吸收的新型O-木糖苷7c的发现。
• COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2
  申请人：CHEN Jinling

  公开号：US20120172320A1

  公开（公告）日：2012-07-05

  Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

  本发明揭示了用于改善心血管和/或代谢健康的药物剂型，特别是用于治疗2型糖尿病患者的药物剂型，以及其制造方法。
• Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use
  申请人：Goodwin Nicole C.

  公开号：US20080221164A1

  公开（公告）日：2008-09-11

  Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.

  揭示了可能对治疗疾病和疾病，如糖尿病和肥胖症有用的化合物和制药组合物。
• INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE
  申请人：Harrison Bryce Alden

  公开号：US20080113922A1

  公开（公告）日：2008-05-15

  Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.

  本发明揭示了化合物及包含它们的制药组合物，可用于治疗疾病和疾病，如糖尿病和肥胖症。
• SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE
  申请人：HARRISON Bryce Alden

  公开号：US20140135277A1

  公开（公告）日：2014-05-15

  Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

  本发明揭示了基于Sulfanyl-tetrahydropyran的化合物，包括它们的药物组合物，并且揭示了它们用于治疗糖尿病和肥胖症等疾病和障碍的方法。